The response rate for patients with the FCGR2A R/R genotype was significantly increased when cetuximab was added to Nordic FLOX ( 31 % versus 53 % , interaction P = 0.03 ) , but was not significantly different compared to the response rate of patients with the FCGR2A H/H or H/R genotypes given the same treatment .